RT other
T1 Drug survival of systemic and biological treatments for moderate-to-severe atopic dermatitis in adults: a multicentre retrospective observational study
A1 Pereyra-Rodríguez, José Juan
A1 Dominguez-Cruz, Javier
A1 Ruiz-Villaverde, Ricardo
A1 Silvestre-Salvador, Juan Fancisco
A1 Galán Gutiérrez, Manuel
A1 Curto-Barredo, Laia
A1 Figueras-Nart, Ignasi
A1 Serra-Baldrich, Esther
A1 Armario Hita, José Carlos
A2 Cirugía
A2 Medicina
K1 atopic dermatitis
AB This study provides a comparative survival analysis among most treatments available for moderate-to-severe AD. Regarding systemic drug survival, our findings are in reasonableagreement with previous studies. Considering survival analysis as a reflection of the performance of a drug in daily practice, the results for dupilumab in our study demonstrate a clear superiority in terms of persistence compared with systemictherapy. The dropout rate for the dupilumab group was only 6% in 20 months, whereas it was above 65% for all the other drugs under study. A limitation of this study isthe retrospective design, which is dependent on the quality of the medical records.
PB Oxford University Press
SN 1365-2133
YR 2021
FD 2021-01
LK http://hdl.handle.net/10498/39523
UL http://hdl.handle.net/10498/39523
LA eng
DS Repositorio Institucional de la Universidad de Cádiz
RD 08-nov-2026